TrialGlobe

Clinical trial

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Recruiting now · Not applicable · 1 countries · Registry ID NCT06278285

Recruiting nowNot applicableInterventional

What this study is about

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity

Full registry criteria

Inclusion Criteria: * Patient over 18 years of age. * Patient able to read and understand the information/consent leaflet. * Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40 * Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM. * Membership of a social security scheme * Patient's signed informed consent * For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months. * For non-GLP-1 analogue group: never taken GLP-1 analogues. Exclusion Criteria: * Pregnant or breast-feeding women. * Vulnerable patients (under guardianship) * Patients deprived of liberty

Treatments and study arms

Blood GLP1

Other

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues

Blood No treated GLP1

Other

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.

Primary outcomes

Rate of oxytocinone time (before surgery)

show that subjects treated with a GLP-1 agonist have a significant change in oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

CHU de Nice - Hôpital de l'Archet🇫🇷 Nice, Alpes-maritimes, France
Open map
Roux Christian, PhDContact
Email · Call +33492039220
Iannelli Antonio, PhDContact
Email
Iannelli Antonio, PhDPrincipal Investigator